A Phase 4 interventional study of Risdiplam in Spinal Muscular Atrophy, sponsored by Clinic for Special Children. Active, not recruiting at 1 site in United States. Open to participants aged 2 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Clinic for Special Children · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing risdiplam in Muscular Atrophy, Spinal — none open to participants now, 4 under way, none of them phase 3. Risdiplam · Muscular Atrophy, Spinal.
Among the 13 studies testing risdiplam in Muscular Atrophy, Spinal, this one is the 13th largest by planned enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 10th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →None of the 13 studies testing risdiplam in Muscular Atrophy, Spinal is open now. The open studies under Muscular Atrophy, Spinal, anywhere →
Risdiplam: first FDA approval 2020 (EVRYSDI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 10 is below the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 33 across the 13 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 3 most frequent:
Clinic for Special Children is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Clinic for Special Children has 1 study filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing risdiplam in Muscular Atrophy, Spinal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Risdiplam Exchange (RISE) is a study of spinal muscular atrophy (SMA) patients who crossover to 36 months of open-label risdiplam monotherapy following a comparable period of nusinersen treatment. The schedule of assessments (SOAs) carry over seamlessly for the cohort from studies done while treated with nusinersen and continue to track the most informative outcomes from that trial (e.g. nine hole peg test and grip strength), while adding the Box and Block Test (BBT) as an additional measure of upper limb endurance and function.
Risdiplam is an orally bioavailable small molecule that distributes into the central nervous system (CNS) and peripheral tissues where it modifies SMN2 pre-mRNA splicing and increases tissue SMN protein levels. It was approved by the U.S. Food and Drug Administration for all SMA patients older than 2 months of age in August 2020.
Clinical trial data prompted us to consider risdiplam a reasonable alternative to nusinersen administered intrathecally or by subcutaneous intrathecal catheter (SIC) for patients with more advanced SMA. Considered within this clinical context, risdiplam presents a significant advantage by eliminating the risks of mechanical failure, intrathecal bleeding, and CNS infection associated with the SIC device. The schedule of assessments (SOAs) used in this cohort during the previous three-year period as part of a nusinersen study provide us with an established framework for data collection. Thus, the overall clinical experience with risdiplam as compared to nusinersen can be assessed using a prospective, crossover design in a real-world setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants crossover to 36 months of open-label risdiplam mono therapy following a comparable period of nusinersen treatment.
Drug: Risdiplam
administered to participants per product label insert
Comparative intrasubject performance on nine hole peg test (NHPT)
Time in seconds to place and subsequently remove nine one inch pegs in holes assessed in dominant and non dominant hands
Time frame: 36 months
Intrasubject changes in lower limb and overall motor function
Revised Hammersmith Scale (RHS) of 33 items with grades of 0 (unable),1 (attempted, not completed) and 2 (achieves task); the greater the sum total, the higher overall motor function.
Time frame: 36 months
Intrasubject changes in upper limb motor function
box and block test (BBT): number of 1 inch wood blocks moved from one compartment to an adjacent one over a wall within 5 minutes, with more blocks moved corresponding to higher upper limb motor function
Time frame: 36 months
Intrasubject change in pulmonary function
maximal inspiratory pressure (MIP) and mean expiratory pressure (MEP), measured in centimeters of water displaced
Time frame: 36 months
Frequency and type of adverse events
laboratory testing, self-reported, and observed during the study
Time frame: 36 months
Comparative intrasubject change in grip strength
hand-held dynamometry (MyoGrip and MyoPinch) measures force in Newtons
Time frame: 36 months
Plan to share: No
Started Nov 2022 (actual). Primary completion is estimated for Dec 2025, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risdiplam
Clinic for Special Children